K Zurbonsen, A Michel, D Vittet, P A Bonnet, C Chevillard
Index: Biochem. Pharmacol. 53(8) , 1141-7, (1997)
Full Text: HTML
Phosphodiesterase (PDE) inhibitors were shown to inhibit proliferation of various cell types. The present investigation was designed to study the activity of selective PDE inhibitors (8-MeoMIX, milrinone, trequinsin, rolipram, RO-201724, zaprinast, and MY-5445) on the proliferation of the Dami cell line in relation to their effects on cAMP levels and PDE isoenzymes isolated from Dami cells. All compounds, except 8-MeoMIX, elicited antiproliferative effects. Trequinsin, RO-201724, and MY-5445 (100 microM) were found to inhibit cell growth up to 60%, 83%, and 85%, respectively; milrinone, rolipram and zaprinast elicited only weak effects (19-21% at 100 microM). Their growth-inhibitory effects could not be related to their effects on cAMP levels. In addition, although PDE type III and IV inhibitors potentiated cAMP formation due to adenylycyclase activation, no potentiation could be observed when considering their antiproliferative effect. Separation and characterization of PDE of Dami cells revealed the existence of types III, IV, and V isoenzymes. The PDE inhibition found for the PDE inhibitors could not explain their antiproliferative effects. The lack of correlation with cAMP concentrations or PDE inhibition and the high concentrations needed to elicit antiproliferative effects suggest the implication of other parameters, such as cytotoxicity or lipophilicity, or other targets in addition to PDE for the PDE inhibitors tested. Lipophilicity did not seem to be of importance in antiproliferative effects. In contrast, cytotoxic effects, in particular those of trequinsin and MY-5445, could partially explain their negative action on cell growth.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Trequinsin hydrochloride
CAS:78416-81-6 |
C24H28ClN3O3 |
Pituitary adenylate cyclase activating polypeptide (PACAP) p...
1994-01-01 [Life Sci. 54(22) , 1735-43, (1994)] |
Atrial natriuretic peptide reduces cyclic AMP by activating ...
1994-09-01 [J. Cardiovasc. Pharmacol. 24(3) , 351-7, (1994)] |
Role of cGMP-inhibited phosphodiesterase and sarcoplasmic ca...
2000-10-01 [J. Mol. Cell. Cardiol. 32(10) , 1831-40, (2000)] |
Effects of colforsin, trequinsin and isoprenaline on norepin...
1988-02-01 [Arzneimittelforschung 38(2) , 240-3, (1988)] |
Mutational mapping of kinetic and pharmacological properties...
1994-12-02 [J. Biol. Chem. 269(48) , 30676-81, (1994)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved